GOOD, so this clears up things nicely--let the games begin--Brother Siggi Olaffson wants a fight--will JT take it to him?:
(1) Amarin will wait and then launch their acredited generic version (would be nice if they offered it alone and in combination with a generic statin (ideally atorvastatin) also
(2) Lets see where and when the generic abuse starts up and where the prescribers and the insurance third party payors start fueling the abuse with mandated substitutions without regard to indication. Then the law suits will erupt.I am told presently the HIKMA generic is priced 8.9% below Vascepa pricing but DOES NOT require prior authorization as a generic...(confirmation by real world experience pending)
Our politico CAFC judges clearly want to look the other way while looting is taking place in the name of great generic pricing, H-W philosophy etc., but TEVA vs. GSK has thrown a spanner in the generic war machine, and it will take some time and doing for them to spit it out. I think SCOTUS could very well duck considering Amarin's prima vs. secondary argument considerations, BUT will eventually be forced by the appeals stacking up from various directions, eventually to grant a writ of certiorari, and consider a skinny label arbitration of infringement begins and ends,i.e. a laying down of boundaries for infringement and policing thereof. Meanwhile back at camp nihilism, the CAFC seems happy to drift as always making it up as they go along until they are forced to do otherwise. God help us!
Amen
HK